Question special

There have been significant advancements in development and validation of biomarkers for diseases such as traumatic brain injury (blood GFAP and UCH-L1) Alzheimer’s disease (PET amyloid and tau imaging, CSF amyloid beta). While some of these are still in the research phase, it is only a matter of time before they become clinically available to help diagnose diseases that were previously characterized on clinical features alone. I am curious to hear how one adapts their daily practice to “learn” how to properly use new biomarkers in their clinical decision making.